Total Payments
$1.1M
2024 Payments
$95,887
Companies
42
Transactions
2,162
Medicare Patients
27,979
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$883,122 (79.3%)
Travel$115,703 (10.4%)
Consulting$60,647 (5.4%)
Food & Beverage$52,335 (4.7%)
Education$1,121 (0.1%)
Research$665.28 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $818,450 | 673 | 73.5% |
| Travel and Lodging | $115,703 | 434 | 10.4% |
| Consulting Fee | $60,647 | 29 | 5.4% |
| Food and Beverage | $52,335 | 961 | 4.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $48,852 | 15 | 4.4% |
| Honoraria | $13,320 | 8 | 1.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $2,500 | 1 | 0.2% |
| Education | $1,121 | 40 | 0.1% |
| Unspecified | $665.28 | 1 | 0.1% |
Payments by Type
General
$1.1M
2,161 transactions
Research
$665.28
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $441,170 | 806 | $0 (2024) |
| Novo Nordisk Inc | $251,234 | 400 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $93,813 | 163 | $0 (2022) |
| Dexcom, Inc. | $78,673 | 116 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $72,203 | 142 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $44,409 | 49 | $0 (2022) |
| Mannkind Corporation | $40,296 | 151 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $38,725 | 68 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $31,650 | 54 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,346 | 22 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95,887 | 175 | Lilly USA, LLC ($49,737) |
| 2023 | $111,089 | 223 | Lilly USA, LLC ($55,949) |
| 2022 | $171,011 | 264 | Lilly USA, LLC ($77,398) |
| 2021 | $137,503 | 229 | Lilly USA, LLC ($37,955) |
| 2020 | $78,566 | 180 | Lilly USA, LLC ($44,557) |
| 2019 | $156,234 | 351 | Lilly USA, LLC ($69,735) |
| 2018 | $142,435 | 296 | Novo Nordisk Inc ($50,554) |
| 2017 | $220,870 | 444 | Lilly USA, LLC ($60,940) |
All Payment Transactions
2,162 individual payment records from CMS Open Payments — Page 1 of 87
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | Cash or cash equivalent | $32.16 | General |
| Category: Endocrinology | ||||||
| 12/09/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,160.00 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Durable Pump | ||||||
| 11/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $5.65 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $763.98 | General |
| 11/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $111.10 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,124.00 | General |
| Category: Endocrinology | ||||||
| 11/07/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/07/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,045.93 | General |
| 11/06/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $120.12 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $4.43 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Diabetes | ||||||
| 11/02/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $30.46 | General |
| Category: Diabetes | ||||||
| 11/01/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $772.40 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND STUDY OF EFFICACY AND SAFETY OF DULAGLUTIDE WHEN ADDED TO SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $665.28 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 5,804 | 10,394 | $1.0M | $271,657 |
| 2022 | 49 | 7,647 | 12,809 | $1.3M | $317,961 |
| 2021 | 49 | 8,020 | 13,536 | $1.3M | $348,412 |
| 2020 | 49 | 6,508 | 9,696 | $933,349 | $254,581 |
Total Patients
27,979
Total Services
46,435
Medicare Billing
$1.2M
Procedure Codes
191
All Medicare Procedures & Services
191 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 379 | 1,009 | $428,819 | $103,812 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 203 | 205 | $121,904 | $27,704 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 119 | 174 | $52,458 | $12,728 | 24.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 39 | 39 | $26,975 | $10,994 | 40.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 363 | 910 | $33,670 | $9,382 | 27.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 124 | 124 | $21,080 | $8,919 | 42.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 331 | 669 | $38,555 | $8,754 | 22.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 98 | 292 | $35,316 | $7,933 | 22.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 366 | 947 | $16,972 | $7,931 | 46.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 285 | 718 | $24,412 | $6,835 | 28.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 258 | 397 | $23,423 | $6,535 | 27.9% |
| 82306 | Vitamin d-3 level | Office | 2023 | 138 | 224 | $23,072 | $6,498 | 28.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 27 | 33 | $22,676 | $6,020 | 26.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 317 | 679 | $18,333 | $5,151 | 28.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 204 | 241 | $20,700 | $4,702 | 22.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 127 | 127 | $9,271 | $4,343 | 46.8% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 144 | 144 | $12,244 | $4,067 | 33.2% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 249 | 380 | $12,160 | $3,359 | 27.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 222 | 257 | $19,036 | $2,708 | 14.2% |
| 86141 | Measurement c-reactive protein for detection of infection or inflammation, high sensitivity | Office | 2023 | 197 | 204 | $9,180 | $2,589 | 28.2% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 53 | 67 | $5,690 | $1,837 | 32.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 205 | 553 | $5,530 | $1,761 | 31.8% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 71 | 109 | $5,777 | $1,602 | 27.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 195 | 473 | $4,730 | $1,598 | 33.8% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 24 | 37 | $5,328 | $1,497 | 28.1% |
About Dr. David Kayne, M.D
Dr. David Kayne, M.D is a Specialist healthcare provider based in Encino, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144334533.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kayne, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $95,887 received in 2024. These payments were reported across 2,162 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($818,450).
As a Medicare-enrolled provider, Kayne has provided services to 27,979 Medicare beneficiaries, totaling 46,435 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 191 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine
- Location Encino, CA
- Active Since 08/19/2006
- Last Updated 04/16/2018
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1144334533
Products in Payments
- TRULICITY (Drug) $243,597
- MOUNJARO (Drug) $142,690
- INVOKANA (Drug) $93,407
- Ozempic (Drug) $61,815
- Rybelsus (Drug) $48,383
- AFREZZA (Drug) $40,296
- Tresiba (Drug) $37,366
- Kerendia (Drug) $36,901
- FARXIGA (Drug) $36,567
- RYBELSUS (Drug) $35,085
- DEXCOM G7 GSS (161) (Medical Supply) $32,345
- SOLIQUA (Drug) $29,541
- GVOKE HYPOPEN (Drug) $27,662
- TOUJEO (Drug) $23,336
- Victoza (Drug) $22,502
- DEXCOM G6 TRANSMITTER (Device) $20,857
- Dexcom G6 Transmitter (Medical Supply) $19,587
- SOLIQUA 100/33 (Drug) $8,940
- JARDIANCE (Drug) $7,041
- FIASP (Drug) $6,403
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Encino
Dr. John Joseph, M.d, M.D
Specialist — Payments: $458,108
Specialist $458,108
Dr. Douglas Sears, M.d, M.D
Specialist — Payments: $20,325
Specialist $20,325
Dr. Peyman Ghasri, M.d, M.D
Specialist — Payments: $16,849
Specialist $16,849
Dr. Michael Hollander, M.d, M.D
Specialist — Payments: $3,057
Specialist $3,057
Helene Rosenzweig, M.d, M.D
Specialist — Payments: $2,388
Specialist $2,388
Arthur Kowell, M.d, M.D
Specialist — Payments: $2,297
Specialist $2,297